Literature DB >> 22516258

Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance.

Elizabeth S Nakasone1, Hanne A Askautrud, Tim Kees, Jae-Hyun Park, Vicki Plaks, Andrew J Ewald, Miriam Fein, Morten G Rasch, Ying-Xim Tan, Jing Qiu, Juwon Park, Pranay Sinha, Mina J Bissell, Eirik Frengen, Zena Werb, Mikala Egeblad.   

Abstract

Little is known about the dynamics of cancer cell death in response to therapy in the tumor microenvironment. Intravital microscopy of chemotherapy-treated mouse mammary carcinomas allowed us to follow drug distribution, cell death, and tumor-stroma interactions. We observed associations between vascular leakage and response to doxorubicin, including improved response in matrix metalloproteinase-9 null mice that had increased vascular leakage. Furthermore, we observed CCR2-dependent infiltration of myeloid cells after treatment and that Ccr2 null host mice responded better to treatment with doxorubicin or cisplatin. These data show that the microenvironment contributes critically to drug response via regulation of vascular permeability and innate immune cell infiltration. Thus, live imaging can be used to gain insights into drug responses in situ.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516258      PMCID: PMC3332002          DOI: 10.1016/j.ccr.2012.02.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  44 in total

1.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.

Authors:  Q Yu; I Stamenkovic
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

Review 2.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

3.  TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

Authors:  Abigail F Welford; Daniela Biziato; Seth B Coffelt; Silvia Nucera; Matthew Fisher; Ferdinando Pucci; Clelia Di Serio; Luigi Naldini; Michele De Palma; Gillian M Tozer; Claire E Lewis
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

Review 4.  Tumors as organs: complex tissues that interface with the entire organism.

Authors:  Mikala Egeblad; Elizabeth S Nakasone; Zena Werb
Journal:  Dev Cell       Date:  2010-06-15       Impact factor: 12.270

5.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

Authors:  G Thurston; C Suri; K Smith; J McClain; T N Sato; G D Yancopoulos; D M McDonald
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

6.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

Authors:  David G DeNardo; Donal J Brennan; Elton Rexhepaj; Brian Ruffell; Stephen L Shiao; Stephen F Madden; William M Gallagher; Nikhil Wadhwani; Scott D Keil; Sharfaa A Junaid; Hope S Rugo; E Shelley Hwang; Karin Jirström; Brian L West; Lisa M Coussens
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

Review 7.  Normalization of the vasculature for treatment of cancer and other diseases.

Authors:  Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

8.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Authors:  Tanaya Shree; Oakley C Olson; Benelita T Elie; Jemila C Kester; Alfred L Garfall; Kenishana Simpson; Katherine M Bell-McGuinn; Emily C Zabor; Edi Brogi; Johanna A Joyce
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

9.  Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment.

Authors:  G-One Ahn; Diane Tseng; Cho-Hwa Liao; Mary Jo Dorie; Agnieszka Czechowicz; J Martin Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

10.  DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity.

Authors:  Jennifer L Guerriero; Dara Ditsworth; Joseph M Catanzaro; Gregory Sabino; Martha B Furie; Richard R Kew; Howard C Crawford; Wei-Xing Zong
Journal:  J Immunol       Date:  2011-02-07       Impact factor: 5.422

View more
  216 in total

Review 1.  New development in studies of formyl-peptide receptors: critical roles in host defense.

Authors:  Liangzhu Li; Keqiang Chen; Yi Xiang; Teizo Yoshimura; Shaobo Su; Jianwei Zhu; Xiu-wu Bian; Ji Ming Wang
Journal:  J Leukoc Biol       Date:  2015-12-23       Impact factor: 4.962

Review 2.  Beyond 3D culture models of cancer.

Authors:  Kandice Tanner; Michael M Gottesman
Journal:  Sci Transl Med       Date:  2015-04-15       Impact factor: 17.956

Review 3.  Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.

Authors:  Shivani Srivastava; Stanley R Riddell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

4.  Cancer: Destiny from density.

Authors:  Victoria L Seewaldt
Journal:  Nature       Date:  2012-10-25       Impact factor: 49.962

5.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

6.  In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy.

Authors:  Oliver Jonas; Jeon Woong Kang; Surya P Singh; Alex Lammers; Freddy T Nguyen; Ramachandra R Dasari; Peter T C So; Robert Langer; Michael J Cima
Journal:  Analyst       Date:  2018-10-08       Impact factor: 4.616

7.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

Review 8.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261

9.  Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+ monocytes via CCL2.

Authors:  Hendrik W van Deventer; Daniela A Palmieri; Qing Ping Wu; Everett C McCook; Jonathan S Serody
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

Review 10.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.